Qiagen shares surged more than 15% after Bloomberg reported the diagnostics and life‑science tools company is working with advisers and has received interest from potential buyers. Market chatter cited strategic fits with Agilent, Danaher or other life‑science acquirers and noted the company’s recent moves, including the Parse Biosciences deal and CEO transition. Analysts flagged that leadership change and asset mix (molecular testing plus single‑cell omics) make Qiagen an attractive consolidation target. Qiagen did not comment; the company’s past acquisition attempt by Thermo Fisher in 2020 and continuing sector consolidation add context to the rumors. Speculation underscores ongoing M&A interest in mid‑market diagnostics firms as larger groups seek scale and platform breadth.